双特异性抗体用于治疗复发性/耐火性多发性髓瘤
Paola Tacchetti1, Simona Barbato1,2, Katia Mancuso1,2
1IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia "Seràgnoli", Bologna, Italy.
Cancers
|July 13, 2024
概括
双特异性抗体 (BsAbs) 在复发性/耐药性多发性髓瘤中显示出高响应率. 目前正在进行的研究旨在提高疗效,减少毒性,以改善患者的治疗结果.
科学领域:
- 免疫学 免疫学 免疫学
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 双特异性抗体 (BsAbs) 是为了准T细胞和瘤抗原而设计的.
- 针对BCMA,GPRC5D和FcRH5的BsAbs在复发性/耐药性多发性髓瘤 (RRMM) 中表现出显著的临床活性.
研究的目的:
- 审查多发性骨髓瘤治疗中双特异性抗体的临床活性,安全性和未来方向.
主要方法:
- 在RRMM中对BsAbs进行临床试验数据的审查.
- 分析疗效终点,如总体响应率 (ORR) 和无进展生存期 (PFS).
- 评估安全概况,包括细胞因子释放综合征和细胞衰竭.
主要成果:
- 在重度预治疗的RRMM患者中,单一治疗BsAbs实现了ORR>60%,完全响应 (CR) 率为25-50%,PFS中位数约为1年.
- 已批准的BsAbs针对BCMA或GPRC5D,对于FcRH5.5具有有希望的早期结果.
- 常见的毒性包括细胞因子释放综合征,细胞衰竭和感染;GPRC5D药物可能会导致瘤外的目标效应.
结论:
- BsAbs代表了RRMM的高度有效的治疗选择,提供了相当大的响应率.
- 需要进一步的研究来优化BsAb的疗效,管理毒性,并克服针对个性化治疗策略的耐药性机制.
相关概念视频
01:31Hybridoma Technology
14.4K
Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
14.4K
02:57Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
01:27Tumor Immunotherapy
509
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
509
02:50Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
128
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
128